Literature DB >> 26110682

Epinephrine in anaphylaxis: doubt no more.

T Ted Song1, Phil Lieberman.   

Abstract

PURPOSE OF REVIEW: The purpose of this manuscript is to review the literature in support of epinephrine (adrenaline) as first line of therapy of anaphylaxis, not H-1 antihistamines or corticosteroids. RECENT
FINDINGS: The purpose of this review is to assess that epinephrine has a quick onset of activity and rapidly antagonizes multiple mediators that are active in anaphylaxis. Epinephrine has maximal pharmacodynamic effect within 10 min of intramuscular administration into the thigh. As epinephrine has a narrow therapeutic window, prefilled epinephrine auto-injectors are available. There are weight-appropriate doses of epinephrine available with auto-injectors that are prefilled with 0.15, 0.30 and 0.50 mg. In addition, needle lengths vary from 1.17 to 2.50 cm. Different doses and needle lengths are available for paediatric and adult patients, especially obese patients to ensure intramuscular delivery in the thigh.
SUMMARY: Failure to administer epinephrine promptly has resulted in fatalities. Education about anaphylaxis and prompt treatment are critical for patients and their caregivers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26110682     DOI: 10.1097/ACI.0000000000000185

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  3 in total

1.  Red man syndrome following the use of vancomycin-loaded bone cement in the primary total knee replacement: A case report.

Authors:  Chu-Ting Chen; Khai-Jing Ng; Yu Lin; Ming-Chang Kao
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.889

2.  A systematic review of epinephrine stability and sterility with storage in a syringe.

Authors:  Hannah G Parish; Jacquelyn R Morton; Julie C Brown
Journal:  Allergy Asthma Clin Immunol       Date:  2019-02-21       Impact factor: 3.406

3.  Management of anaphylaxis in the dental practice: an update.

Authors:  Phil Jevon; Shaam Shamsi
Journal:  Br Dent J       Date:  2020-12-11       Impact factor: 2.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.